Medical Devices; General Hospital and Personal Use Devices; Classification of the Diabetes Digital Behavioral Therapeutic Device
What happened
The Food and Drug Administration (FDA) classified the diabetes digital behavioral therapeutic device into class II, effective July 24, 2026, though the classification was applicable on July 7, 2023. This action involved setting "special controls" to ensure device safety and effectiveness. Signed by Donald Trump, this decision allows for the reclassification of devices initially set to class III by law, reducing regulatory burdens.
Why it matters
This reclassification means easier access for patients to innovative diabetes management tools by reducing the regulatory hurdles for manufacturers. It also sets a precedent, allowing similar future devices to go through a less burdensome review process, potentially speeding up their availability.
Who it affects
- ›Patients with diabetes mellitus
- ›Developers of diabetes digital behavioral therapeutic devices
- ›The Food and Drug Administration (FDA)
- ›Medical device manufacturers
The receipts are official. The summary is ours.
Read on Federal Register ↗Summaries are generated from the official text and may simplify or omit nuance. The official document is the source of truth.